Fujifilm’s Chinese pharma patent licensing deal marks a milestone in its IP-driven transformation
Fujifilm announced this week that it had entered into a patent licensing agreement with Chinese company Zhejiang Hisun Pharmaceutical – a transaction that represents the latest step in its realignment as a life sciences-focused business.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.